Skip to content
Screener

Cytokinetics CYTK Financing Cash Flow

Financing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$2.63B-43.2%
Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Merck & Co. logo
Merck & Co.MRK
-$2.98B+48.2%
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
$88.76M+15,617%
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
$12.17M+448%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
$1.47M+2,821%

Other financials

Income statement

See full
Revenue$28.6M-57.1%
Operating income-$179.2M-60.7%
Net income-$198.8M-47.9%
EPS (diluted)-$1.50-33.9%

Balance sheet

See full
Cash & equivalents$255.3M+241%
Total debt$399.0M+31.2%
Total equity-$173.5M+52.9%
Total assets$1.9B+57.0%

Cash flow

See full
Operating cash flow-$159.8M-24.6%
CapEx$4.3M+4.6%
Free cash flow-$164.2M-24.0%

Valuation

See full
Market cap$10.71B+155%
Enterprise value$10.85B+145%
P/S158.2×+109×

Profitability

See full
Operating margin-1,046.1%+1,858pp
Net margin-1,321.1%+8,702pp
FCF margin-858.2%+1,799pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio6.7×-0.1×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:30 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338217
Line itemSix Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Proceeds from issuance of common stock related to public offering, net of issuance costs760,149
Proceeds from issuance of common stock under equity incentive and stock purchase plans49,34814,396
Taxes paid related to net share settlement of equity awards(2,327)(527)
Net cash provided by financing activities800,62783,287
Effect of exchange rate changes on cash(1,078)(952)
Net increase (decrease) in cash, cash equivalents, and restricted cash132,746(18,681)
Cash, cash equivalents, and restricted cash, beginning of period125,63295,232
Cash, cash equivalents, and restricted cash, end of period$258,378$76,551

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Cytokinetics's financing cash flow?
Cytokinetics (CYTK) reported financing cash flow of $792.86M in Q2 2026.
How has Cytokinetics's financing cash flow changed year-over-year?
Cytokinetics's financing cash flow increased by 909.6% year-over-year, from $78.53M to $792.86M.
What is the long-term trend for Cytokinetics's financing cash flow?
Over 4 years (2021 to 2025), Cytokinetics's financing cash flow has grown at a 13.1% compound annual growth rate (CAGR), from $319.98M to $524.46M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Cytokinetics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude